Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even Covered
The cost of GLP-1 weight loss drugs like Ozempic and Wegovy is significantly increasing healthcare expenses for both employers and employees. A recent Milliman Medical Index report indicates a 7.2% rise in annual family healthcare costs, with pharmacy spending, largely driven by these drugs, growing by 14.8%. Consequently, employers are considering limiting coverage or increasing patient co-pays and deductibles to manage these escalating costs. AI
IMPACT Minimal direct impact on AI operators; focuses on pharmaceutical cost trends.